RESUMEN
OBJECTIVE Currently discussing the clinical treatment of pulmonary fibrosis commonly used drugs astragalus main active ingredient astragalosideⅣ(ASTⅣ)in vitro after transforming growth factor-β1 induced lung adenocarcinoma A549 epithelial cells after epithelial cell interstitial Epithelial-Mesenchymal Transition(EMT). METHODS The effect of astragalosideIV on the proliferation of A549 cells was detected by MTT assay for the first time.No significant effect of astragaloside on the prolifera-tion of A549 cells was found in the range of 1.25-20 μmol/L. A549 cells in vitro were divided into 5 groups: normal group, control group, low, medium and high experimental groups, which were treated for 72 hours,and the morphological changes of cells in each group were observed by light microscope. Real-time quantitative PCR (qPCR) and Western blotting were performed. Detection of gene and protein expression levels. RESULTS The results of real-time fluorescence quantitative PCR showed that the quantitative analysis of high-dose astragalosideⅣin the experimental group was lower than that of the control group in the α-SMA analysis,and the difference was statistically significant(P<0.05).The dose of AstragalosideⅣ in the experimental group was higher than that of the control group in the E-Cad analysis,and the difference was statistically significant(P<0.05).Western Blot results showed that the expression of α-SMA antibody in the high-dose and low-dose experimental group was lower than that in the control group, the difference was statistically significant (P<0.05). The high-dose experimental group had a significantly higher expression of E-Cad antibody than the control group, the difference was statistically significant (P<0.01). CONCLUSION This study uses A549 epithelial cells as a model, A549 cells were modeled and confirmed that Astragaloside can effectively inhibit TGF-β1-induced epithelial-mesenchymal transition(EMT)and provide a new basis for the treatment of pulmonary fibrosis.